Vaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1

June 23, 2022

Stay up to date

Get the latest on cutting edge developments from our enterprises straight to your inbox